UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos

UCB just dropped two billion dollars upfront on Candid Therapeutics — their second billion-dollar immunology acquisition in three weeks.

Layer in an FDA withdrawal proposal over data manipulation, the first approved PROTAC, and three-point-two billion in biotech IPOs so far this year — and you have a week that reset several conversations at once.

Welcome to The Pharma Closeout Weekend Edition for Sunday, May 3, 2026. I'm Alex Mercer.

And I'm Maya Patel. A lot happened this week that deserves a second look. Let's get into it.

The headline that dropped just hours ago. UCB announced today it's acquiring Candid Therapeutics for up to two-point-two billion dollars — two billion upfront, two hundred million in milestones. Candid is privately held, clinical-stage, building T-cell engagers for autoimmune and inflammatory diseases.

The lead asset is cizutamig — a bispecific directed at BCMA on plasma cells and CD3 on T cells. UCB's press release says it's been evaluated in over a hundred patients across myeloma and autoimmune indications and is currently in studies across more than ten autoimmune diseases. They're positioning it as a potential best-in-class BCMA T-cell engager for autoimmune.

Here's what elevates this beyond a single deal. Three weeks ago, UCB made a significant acquisition of Neurona Therapeutics in epilepsy. In less than a month, they've committed substantial capital across two distinct therapeutic platforms. UCB has decided its growth story is inorganic.

Look at the design intent behind cizutamig. It was purpose-built to maintain cytotoxicity while limiting cytokine release — the developers engineered from day one around the tolerability constraints that have kept T-cell engagers confined to oncology settings. You don't build a molecule that way unless you're planning for chronic dosing in autoimmune populations from the start.

UCB's CEO Tellier called cizutamig a "potentially transformative asset" and framed it alongside their recent Antengene transaction as platform-driven strategy in next-generation immunology. The logic: assemble multi-target coverage across B-cell biology rather than ride a single molecule.

The tension is timeline. Cizutamig is Phase 1 across autoimmune indications. Two billion upfront for a Phase 1 asset commands a premium even by current standards. Whether UCB's immunology infrastructure — built around Bimzelx and their broader portfolio — can compress development timelines before the competitive landscape fills in is what determines whether this price holds up.

The space is already filling. Gilead paid two-point-two billion for Ouro Medicines in late March — another autoimmune T-cell engager. These premiums reflect conviction, not caution. But if UCB runs cizutamig through multiple indications in parallel, the per-indication cost of that two billion starts looking more defensible.

Step back from UCB specifically. When multiple large pharma companies pay north of two billion for clinical-stage autoimmune T-cell engagers within weeks of each other, you're watching a collective bet that targeted immune reset is the next major therapeutic paradigm. Whether the biology delivers on that bet over five years determines if these prices look visionary or reckless.

UCB-Candid didn't happen in isolation. Shifting to the deal landscape for the full week — Teva paid seven hundred million upfront for Emalex Biosciences, picking up ecopipam for pediatric Tourette syndrome. It's a selective dopamine D1 receptor antagonist with Orphan Drug and Fast Track designations — Jefferies called it Teva's largest acquisition in a decade. NDA submission is expected in the second half of this year, with with additional commercial milestones and royalty payments tied to future sales.

The mechanism is the story. Teva's own announcement notes that currently approved Tourette medications act primarily on D2 receptors — ecopipam goes after D1. For clinicians who've managed pediatric patients through the side-effect profile of D2 agents, that mechanistic separation carries real weight.

Beyond Teva — Lilly acquiring Ajax Therapeutics for up to two-point-three billion in hematology. Chiesi signing one-point-nine billion for KalVista in rare disease. Esperion going private with ArchiMed at up to one-point-one billion — a substantial per-share cash component, plus supplemented by contingent payments contingent on clinical or regulatory outcomes. Those shares once traded above a hundred fifteen dollars back in 2015. And on the earnings front, Moderna posted Q1 revenue of three hundred eighty-nine million, up two hundred sixty percent year over year, though its loss widened to three-forty per share from two-fifty-two a year ago.

Let's bring in Marcus Webb on the broader M&A picture. Marcus, what does this velocity tell us?

And the capital markets are reinforcing that signal. Ten biotech IPOs have banked roughly three-point-two billion year to date — six raising at least three hundred million, two surpassing four hundred million. Hemab and Seaport Therapeutics alone combined for five hundred fifty-six million in upsized IPOs last week. When both the M&A and IPO pipelines run at this pace simultaneously, 2026 stops being a recovery year and starts resetting what normal dealmaking looks like in this sector.

All that deal activity dominated headlines. But on the regulatory front, the most consequential FDA action of the week wasn't an approval — it was a withdrawal proposal. On April 30th, the agency formally proposed withdrawing approval of Amgen's Tavneos — avacopan — alleging the original submission contained untrue statements and manipulated clinical data. The FDA's letter states there is, quote, "a lack of substantial evidence that Tavneos will demonstrate efficacy."

That language is extraordinary. This isn't a safety signal or a labeling dispute — the agency is alleging the evidence base itself was fabricated.

And the FDA almost never pursues this pathway. Tavneos remains on the market while proceedings play out — Amgen can request a hearing before the Commissioner through its ChemoCentryx subsidiary. But Amgen reported strong Tavneos sales growth in Q1, showing significant year-over-year growth. A commercially accelerating franchise now facing an existential regulatory challenge. The reputational exposure stretches well beyond one product.

Amgen is reportedly filing a label update for Tavneos concurrently — which reads like a company trying to shore up the franchise while the legal clock runs.

Contrast that with what happened on the approval side. The FDA approved Veppanu — vepdegestrant — from Pfizer and Arvinas on May 1st for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. According to Arvinas' announcement and the FDA's novel drug approval list, Veppanu is the first approved PROTAC protein degrader. Endpoints characterized the data as "underwhelming," and the companies plan to hand off commercialization to a partner they haven't yet identified.

A first-in-class mechanism crossing the finish line and the developers immediately shopping for someone else to sell it — that tells you everything about where they see the platform versus the commercial reality of a narrowly selected population.

The ESR1 mutation-selected label is the more interesting clinical story. These patients have progressed on prior endocrine therapy — the ceiling is lower than broad ER-positive disease, but the unmet need in this niche is genuine. How the launch partner frames the value proposition for a protein degrader in this population will say a lot about how the PROTAC platform evolves commercially.

Also worth noting — Axsome's Auvelity won an FDA label expansion for Alzheimer's disease agitation, adding a second indication that meaningfully extends that brand's commercial life.

And then Summit. Ivonescimab missed statistical significance at a pre-planned interim analysis of the Phase 3 Harmoni-3 trial — first-line non-small cell lung cancer, tested against Keytruda. Shares experienced a notable decline. Stifel's analyst called it a "self-inflicted narrative complication" — Summit added this interim analysis earlier this year, and the decision backfired. But here's what the selloff may be overweighting: the alpha allocated to the interim was minimal, meaning the statistical threshold was extraordinarily high by design. This preserved power for the final analysis expected in the second half. It's a painful headline, not necessarily a broken program — and Summit still holds a plenary slot at ASCO.

Amgen had its own pipeline reckoning this week — discontinuing adezkibart for Sjogren's after a Phase 2 futility analysis and terminating four trials of anvumetostat across multiple tumor types for insufficient efficacy. multiple terminated trials disclosed simultaneously.

Take the Tavneos withdrawal, the Summit miss, and the Amgen cuts together and the pattern speaks for itself. Whether the bar is data integrity or clinical efficacy, assets that can't clear it are being removed from the board. That discipline is healthy for the sector, even when the individual stories sting.

Under the radar this week — Pfizer quietly settled patent disputes with three generic manufacturers over Vyndamax, its tafamidis franchise for transthyretin cardiomyopathy. Dexcel, Hikma, and Cipla all agreed to terms that, according to BioPharma Dive, extend tafamidis' U.S. market exclusivity into the early 2030s.

This landed while everyone was watching deal announcements and FDA actions. But the downstream effect is significant — every company with a development program in the ATTR-CM space just saw the competitive clock reset. Generic entry pushed out by years changes pricing assumptions, market access modeling, and the return profile for competing molecules still in trials.

Looking at the week ahead — May is loading up fast. On May 10th, argenx faces its Vyvgart sBLA decision for seronegative generalized myasthenia gravis under Priority Review.

That one deserves close attention. Seronegative gMG patients have been systematically underserved — historically excluded from trials and left without targeted options. If Vyvgart clears this bar, it doesn't just expand a label. It validates the thesis that FcRn blockade works across antibody subtypes, and that has read-through for how the entire class gets developed going forward.

May 18th brings the Enhertu sBLA from Daiichi Sankyo and AstraZeneca for neoadjuvant HER2-positive breast cancer. May 24th, Eisai and Biogen's Leqembi IQLIK decision for a subcutaneous starting dose in early Alzheimer's. And Moderna is in active talks with the FDA over post-marketing Covid vaccine data that could restore broader access — developments there are worth tracking.

And behind all of it — ASCO. The annual meeting runs May 29th through June 1st in Chicago, abstracts are imminent, and Summit's ivonescimab still holds that plenary slot despite this week's miss. Depending on what the full dataset shows, the narrative around that program could reverse course entirely. This month will separate the assets with durable data from the ones running on momentum alone.

That wraps our Weekend Closeout for May 3rd. UCB's two-billion-dollar bet on Candid, the FDA alleging data fabrication behind Tavneos, Veppanu becoming the first approved PROTAC, Teva's seven-hundred-million Tourette play, and Summit's stumble heading into ASCO — every one of those stories will still be shaping decisions weeks from now. If this briefing helps you stay across the space, follow us on Spotify and drop a rating — it makes a real difference. We're back tomorrow.

Enjoy your Sunday evening. See you tomorrow.